1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Nektar Meets Failure Again, This Time In Phase II Lupus Study

 
• By Alaric DeArment

Nektar, which had multiple trial failures for cancer drug bempegaldesleukin last year, and Lilly will now focus on rezpegaldesleukin in atopic dermatitis. Nektar is planning significant cost reductions.

Nektar said the Phase II study of rezpeg in SLE failed • Source: Shutterstock

Nektar Therapeutics has encountered another failure of a drug in its pipeline, this time rezpegaldesleukin moderately to severely active systemic lupus erythematosus (SLE). The trial failure means neither it nor partner Eli Lilly and Company will move forward in that indication, though the companies are discussing next steps for a Phase IIb study of it in atopic dermatitis, and Nektar executives suggested that a future path forward in lupus may still exist as well.

Nektar announced topline data on 23 February from its Phase II randomized, placebo-controlled trial of rezpegaldesleukin in adults with SLE who had received standard-of-care treatment like corticosteroids, antimalarials and non-biological immunosuppressants

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.